- Trials with a EudraCT protocol (2,601)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2,601 result(s) found for: Genetic Disease.
Displaying page 1 of 131.
EudraCT Number: 2008-001174-33 | Sponsor Protocol Number: 28612 | Start Date*: 2008-12-30 | |||||||||||
Sponsor Name:Merck Serono International S.A., A branch of Laboratoires Serono S.A. | |||||||||||||
Full Title: A mulitnational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® ... | |||||||||||||
Medical condition: Females undergoing assisted reproductive technology (ART), in vitro fertilisation (IVF) or intra cytoplasmic sperm injection (ICSI) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) FR (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003938-32 | Sponsor Protocol Number: 11190801 | Start Date*: 2014-02-12 |
Sponsor Name:Medizinische Universität Graz | ||
Full Title: Genetic alterations in genes coding for transporters and metformin resistance | ||
Medical condition: We want to investigate the pharmacokintetics of metformin in patients with type 2 diabetes or polycystic ovary syndrome in association with the patients genotype | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004008-36 | Sponsor Protocol Number: ANAK-01 | Start Date*: 2005-10-27 | |||||||||||
Sponsor Name:ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Efficacy and safety of treatment with Anakinra in patients with CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis | |||||||||||||
Medical condition: CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002319-86 | Sponsor Protocol Number: DIAN-Obs-BCN | Start Date*: 2019-03-20 |
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
Full Title: Dominantly Inherited Alzheimer Network - DIAN | ||
Medical condition: Alzheimer disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002210-12 | Sponsor Protocol Number: ID-069A302 | Start Date*: 2019-03-18 | ||||||||||||||||
Sponsor Name:Idorsia Pharmaceuticals Ltd | ||||||||||||||||||
Full Title: A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease | ||||||||||||||||||
Medical condition: Fabry disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) FR (Ongoing) AT (Ongoing) NL (Completed) BE (Ongoing) NO (Ongoing) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005032-30 | Sponsor Protocol Number: FLT201-01 | Start Date*: 2023-03-13 | ||||||||||||||||
Sponsor Name:Freeline Therapeutics Limited | ||||||||||||||||||
Full Title: A Phase 1/2, open-label, safety, tolerability and efficacy study of FLT201 in adult patients with Gaucher disease Type 1 (Galileo-1) | ||||||||||||||||||
Medical condition: Type 1 Gaucher Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000763-41 | Sponsor Protocol Number: FBB-FAD-2014 | Start Date*: 2014-08-20 | |||||||||||
Sponsor Name:FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA | |||||||||||||
Full Title: Study of genetic Alzheimer?s disease mutation carriers in preclinical stages of the disease: 18F-Florbetaben Positron Emission Tomography study. | |||||||||||||
Medical condition: Healthy voulnteers carrying a mutation in at least one of the following genes: PSEN1, PSEN2 or APP. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001501-41 | Sponsor Protocol Number: 156-13-208 | Start Date*: 2016-01-16 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | ||
Full Title: A Multinational Trial to Collect Blood Samples to Explore Potential Genetic/Biomarkers Related to Increased Risk of Liver Injury in Adult Subjects from Prior Tolvaptan Clinical Trials for Autosomal... | ||
Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD), Patients with Increased Risk of Liver Injury | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001118-32 | Sponsor Protocol Number: EP06-401 | Start Date*: 2011-05-25 | |||||||||||||||||||||
Sponsor Name:Sandoz GmbH | |||||||||||||||||||||||
Full Title: Twelve-month study on the immunogenicity, safety, and efficacy of Zarzio®/Filgrastim HEXAL® in patients with severe chronic neutropenia | |||||||||||||||||||||||
Medical condition: Severe chronic neutropenia (i.e. congenital neutropenia, cyclic neutropenia and chronic idiopathic neutropenia) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-015985-75 | Sponsor Protocol Number: HGT-REP-060 | Start Date*: 2010-02-03 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies (HGT), Inc. | |||||||||||||
Full Title: An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal Enzyme Replacement Therapy Administered to Adult Patients with Fabry Disease | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) CZ (Completed) GB (Completed) FI (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005796-14 | Sponsor Protocol Number: 1/2013 | Start Date*: 2014-05-13 |
Sponsor Name:Medizinische Universität Wien | ||
Full Title: A randomized, pilot study to assess the impact of single nucleotide polymorphisms in the ABCB1 and ABCG2 genes on brain and organ distribution of dual Pgp/BCRP substrates in humans. | ||
Medical condition: The effect of genetic polymorphisms on drug distribution will be investigated in healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-003297-27 | Sponsor Protocol Number: NLRC4/XIAP.2016.001 | Start Date*: 2019-10-15 |
Sponsor Name:AB2 Bio Ltd. | ||
Full Title: Multicenter, double-blind, placebo-controlled, randomized withdrawal trial with Tadekinig alfa (r-hIL-18BP) in patients with IL-18 driven monogenic autoinflammatory conditions: NLRC4 mutation and X... | ||
Medical condition: NLRC4 mutation XIAP deficiency | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003427-38 | Sponsor Protocol Number: HGT-GCB-068 | Start Date*: 2016-04-07 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies | |||||||||||||
Full Title: A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents With Type 3 Gaucher Disease | |||||||||||||
Medical condition: Type 3 Gaucher disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001309-34 | Sponsor Protocol Number: VX14-809-106 | Start Date*: 2017-03-29 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3b, Open-Label Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Cystic Fibrosis and Advanced Lung Disease, Homozygous for the F508del-CFTR ... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003907-16 | Sponsor Protocol Number: SPIMD-301 | Start Date*: 2022-03-02 | |||||||||||||||||||||
Sponsor Name:Stealth BioTherapeutics Inc. | |||||||||||||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondr... | |||||||||||||||||||||||
Medical condition: Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Ongoing) NO (Ongoing) ES (Ongoing) IT (Ongoing) NL (Ongoing) DE (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000368-27 | Sponsor Protocol Number: MAN-ALG-18-001 | Start Date*: 2018-10-22 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: ND | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004577-30 | Sponsor Protocol Number: EARLY-GENE | Start Date*: 2022-03-11 |
Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO MAJADAHONDA | ||
Full Title: EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriers of Dilated Cardiomyopathy (EARLY-GENE trial) | ||
Medical condition: Dilated Cardiomyopathy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002855-12 | Sponsor Protocol Number: RM-493-034 | Start Date*: 2022-04-22 |
Sponsor Name:Rhythm Pharmaceuticals Inc. | ||
Full Title: A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Rece... | ||
Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) DE (Ongoing) ES (Ongoing) NL (Ongoing) GR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001678-40 | Sponsor Protocol Number: CACZ885N2301E2 | Start Date*: 2017-05-15 | |||||||||||
Sponsor Name:Novartis pharma AG | |||||||||||||
Full Title: An extension study of safety of canakinumab in Japanese patients with periodic fever syndromes | |||||||||||||
Medical condition: Three disease of periodic fever syndromes, TNF receptor Associated Periodic Syndrome (TRAPS), Hyper IgDSyndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002856-33 | Sponsor Protocol Number: ALN-TTRSC-002 | Start Date*: 2013-11-15 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac Amyloidosis | |||||||||||||
Medical condition: Transthyretin (TTR) Cardiac Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.